Progressive-ratio performance in the rhesus monkey maintained by opiate infusions
Progressive-ratio performance in the rhesus monkey maintained by opiate infusions
复制标题
通过鸦片输注维持恒河猴的进步比率表现
DOI：
10.1007/bf00427134
复制
发表时间：
1979
影响因子：
3.4
通讯作者：
F. Hoffmeister
中科院分区：
文献类型：
--
作者：
F. Hoffmeister
在恒河猴体内，采用药物维持递增比率程序比较海洛因、可待因、右旋丙氧酚和五氮唑辛。这些药物的注射取决于每次注射后不同超时时间的固定比率(FR)反应要求的完成情况。在药物试验之前，根据FR 100的完成，以1000微克/公斤的可待因输注建立稳定的自我输注性能。这一标准剂量的可待因被研究药物的剂量所取代。FR需求每天增加一倍，直到每天自行输液的次数减少到不到两次(最大可能：每天八次输液)。这种输液次数的减少被称为临界点。试验剂量范围为海洛因1-500微克/公斤，可待因10-16,000微克/公斤，右丙氧酚50-10,000微克/公斤，五唑西林50-10,000微克/公斤。海洛因以剂量依赖的方式增加断裂点，最高可达12,800的FR要求。这也适用于可待因，最大断裂点发生在FR 6400。右丙氧芬和五唑西林的剂量曲线在5000微克/公斤的输注剂量下达到平台值。在这个剂量下，断裂点是FR 6400。进一步增加这两种药物的输注剂量，可使转折点降至生理盐水水平。这些药物特定剂量转折点函数补充了在其他动物实验中获得的增强特性的信息，并与有关所研究药物滥用倾向的临床药理学信息相对应。
Heroin, codeine, dextropropoxyphene, and pentazocine were compared using a drug-maintained progressive-ratio procedure in the rhesus monkey.Infusions of the drugs were contingent on completion of increasing fixed ratio (FR) response requirements with variable time-out periods following each infusion. Prior to drug experiments, stabile self-infusion performance was established with 1000 mcg/kg codeine infusions contingent on completion of a FR 100. Doses of study drugs were substituted for this standard dose of codeine. FR requirements were doubled daily until the number of self-administered infusions per day decreased to less than two infusions (maximal possible: eight infusions/day). This decrease in the number of infusions is referred to as the breaking point. The dose ranges tested were 1–500 mcg/kg of heroin, 10–16,000 mcg/kg of codeine, 50–10,000 mcg/kg of dextropropoxyphene, and 50–10,000 mcg/kg of pentazocine. Heroin increased breaking points dose dependently up to a FR requirement of 12,800. This applies to codeine also, the maximum breaking point occurring at FR 6400. The breaking-point dose curves of dextropropoxyphene and pentazocine plateaued at an infusion dose of 5000 mcg/kg. At this dose the breaking point was a FR 6400. Further increase of infusion doses of these two drugs decreased breaking points to the saline level. These drug-specific dose breaking-point functions supplement information on reinforcing properties achieved in other animal experiments and correspond with the clinical pharmacologic information about the abuse liability of the studied drugs.